Naslov
Verification of lipemia interference for routine clinical chemistry

Autori
Nikolac, Nora ; Mikša, Manuela ; Saračević, Andrea ; Šimundić, Ana-MAria

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Biochemia Medica / Šimundić, Ana-Maria - Zagreb : Hrvatsko društvo za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM), 2013, A49-A49

Skup
2nd EFLM-BD European Conference on Preanalytical Phase: Preanalytical quality improvement – in quality we trust

Mjesto i datum
Zagreb, Hrvatska, 01.03.2013. - 02.03.2013

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
interference; lipemia; analytical specifications

Sažetak
Background: Lipemia interferes with large number of laboratory tests. In order to assess the extent of lipemia, each manufacturer of laboratory reagents should provide data on interference as part of analytical specification of the test. Laboratory customers should verify those recommendations in laboratory setting. Aim of this study was to verify manufacturer’s specifications regarding lipemia for Beckman Coulter clinical chemistry parameters. Also, since allowable bias by manufacturer was arbitrary (3, 5 or 10%), we aimed to compare our results with desirable specifications for imprecision derived from intra- and inter-individual biologic variation. Materials and methods: In 20 different serum pools following parameters were determined: total and direct bilirubin, urea, creatinine, glucose, calcium, AST, ALT, CK, CK-MB, LD, ALP, GGT, amylase, lipase, total proteins, CRP, phosphates, magnesium, iron, albumin, sodium, potassium and chlorides. All measurements were performed on Beckman Coulter AU680 analyzer (Tokio, Japan) using original reagents and applications as recommended by manufacturer (Beckman Coulter, Inc., Brea, CA, USA). Samples were then spiked with triglyceride rich infusion of 20%-Intralipid® (Fresenius Kabi AB, Uppsala, Sweden) in series of concentrations corresponding to cut-off values declared by manufacturer (100, 300, 500, 700, 800, 900 and 1000 mg/dL Intralipid®) and analytes were determined in each sample. Bias was calculated for each concentration and compared to declared specification. Results: Out of 24 tested parameters, manufacturers recommendations were confirmed for 12 (lipase, direct bilirubin, urea, calcium, total proteins, CRP, iron, GGT, albumin, sodium, potassium, chlorides). However, declared bias of lipemic samples was met at lower Intralipid® concentration for 8 analytes (bilirubin, AST, CK, CK-MB, LD, amylase, magnesium and ALP) suggesting stronger influence of lipemia than declared by manufacturer. Also, for 4 analytes (creatinine, glucose, ALT, phosphates) we have observed higher acceptable cut-off value than specified. The most significant deviation was observed for CK, magnesium and amylase (manufacturers cut-off vs. laboratory cut off: 1000 vs. 300 mg/dL Intralipid®). Conclusions: Our results indicate significant differences in lipemia interference compared to manufacturer’s recommendations for Beckman Coulter clinical chemistry parameters.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA